Agenda for November 2026 Pharmacology and Therapeutics advisory committee (PTAC) meeting

Information on what the Pharmacology and Therapeutics Advisory Committee (PTAC) will be considering at its upcoming meeting in November 2026.

Dienogest (Visanne or generic) for endometriosis

The Committee will discuss an application for dienogest as a first-line hormonal treatment for people with endometriosis. Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, which can cause pain and other symptoms.

Relugolix with oestradiol and norethisterone acetate (Ryeqo) for endometriosis

The Committee will discuss an application for relugolix with oestradiol and norethisterone acetate (Ryeqo) as a second-line hormonal treatment for people with endometriosis who have previously received medical and/or surgical treatment and require ongoing management.

Faricimab for neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) previously been treated with aflibercept.

Aflibercept (Eylea) for wet age-related macular degeneration, 3rd-line.

Switching between aflibercept and faricimab when clinically indicated.

Neovascular (wet) age-related macular degeneration (wAMD) and diabetic macular oedema (DMO) affect the retina and can cause worsening vision and, if left untreated, may lead to vision loss.  These three applications will be considered as part of a broader review of third-line vascular endothelial growth factor (anti-VEGF) treatments for wAMD and DMO.

The Committee will discuss an application for zolmitriptan for the treatment of migraine attacks. Migraine is a neurological condition that can cause severe headaches and symptoms such as nausea and sensitivity to light and sound.

Diabetic Oral Feed (Glucerna Liquid 220mL and Powder 800g) for nutritional support